Global investors must support pharma solidarity and collaboration in the response to COVID-19
The prospect of having the first supplies of at least a few effective COVID-19 medicines and vaccines by the end of 2020 is a key driver of recent market optimism.
- 29 September 2020
- 2 min read
he prospect of having the first supplies of at least a few effective COVID-19 medicines and vaccines by the end of 2020 is a key driver of recent market optimism. New treatments and vaccines are among the best bets for our societies against the risk of recurring COVID-19 flare-ups and persistent lockdowns into 2021.
Yet many experts are questioning whether current research and manufacturing efforts can deliver these medical breakthroughs as quickly as they are being promised. They also warn that anything short of a truly global effort to reach at-risk individuals in richer and poorer countries alike risks prolonging the pandemic, as well as supply and demand constraints, into the future.
This is why we are calling on our global pharma investor colleagues to step up their engagement activities and ask all governments and pharmaceutical companies to fully embrace the principles of collaboration and solidarity in our response to COVID-19. The process of developing, manufacturing, and distributing new medicines and vaccines will be faster and more efficient if governments and pharmaceutical companies work cooperatively and avoid a competitive race based on medical nationalism.
